Timothy Edward Lee Sells 29,643 Shares of Invivyd (NASDAQ:IVVD) Stock

Key Points

• Timothy Edward Lee sold 29,643 shares of Invivyd stock at an average price of $0.57, resulting in a total transaction of approximately $16,896.51.
• Invivyd reported earnings of ($0.12) per share for the last quarter, missing estimates by ($0.08), with revenue falling short at $11.79 million compared to expectations of $23.16 million.
• JPMorgan Chase & Co. significantly increased its position in Invivyd shares by 644.1% during the fourth quarter, acquiring an additional 222,375 shares.

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) insider Timothy Edward Lee sold 29,643 shares of the firm's stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $0.57, for a total transaction of $16,896.51. Following the sale, the insider owned 59,344 shares of the company's stock, valued at approximately $33,826.08. The trade was a 33.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Timothy Edward Lee also recently made the following trade(s):

• On Monday, August 18th, Timothy Edward Lee sold 20,013 shares of Invivyd stock. The shares were sold at an average price of $0.65, for a total transaction of $13,008.45.

Invivyd Stock Performance

Shares of NASDAQ IVVD traded down $0.0101 during midday trading on Tuesday, reaching $0.5710. 1,690,635 shares of the stock were exchanged, compared to its average volume of 850,421. The stock has a market capitalization of $68.60 million, a P/E ratio of -0.62 and a beta of 0.51. The company has a 50 day simple moving average of $0.75 and a 200 day simple moving average of $0.84. Invivyd, Inc. has a twelve month low of $0.3546 and a twelve month high of $2.74.

Invivyd (NASDAQ:IVVD - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.08). The business had revenue of $11.79 million during the quarter, compared to analysts' expectations of $23.16 million. Invivyd had a negative return on equity of 177.89% and a negative net margin of 238.33%. On average, research analysts expect that Invivyd, Inc. will post -1.64 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. D. Boral Capital decreased their price objective on shares of Invivyd from $9.00 to $3.00 and set a "buy" rating on the stock in a report on Friday. HC Wainwright restated a "buy" rating and set a $5.00 price target on shares of Invivyd in a research note on Thursday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $3.85.

Hedge Funds Weigh In On Invivyd

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its position in shares of Invivyd by 644.1% during the fourth quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company's stock worth $114,000 after acquiring an additional 222,375 shares during the period. Renaissance Technologies LLC purchased a new position in Invivyd in the fourth quarter valued at $74,000. Barclays PLC grew its stake in Invivyd by 7.8% during the 4th quarter. Barclays PLC now owns 127,180 shares of the company's stock worth $56,000 after purchasing an additional 9,207 shares in the last quarter. Jane Street Group LLC increased its holdings in Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock worth $52,000 after purchasing an additional 87,358 shares during the period. Finally, Deutsche Bank AG raised its position in Invivyd by 35.2% in the 4th quarter. Deutsche Bank AG now owns 874,406 shares of the company's stock valued at $385,000 after purchasing an additional 227,463 shares in the last quarter. Hedge funds and other institutional investors own 70.36% of the company's stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.